More from DAPA-HF: Dapagliflozin quickly reduces heart failure events
February 22, 2021
Secondary analysis of DAPA-HF showed dapagliflozin significantly cut CV deaths or worsening heart failure within 28 days on treatment.
Quick byte: Curing diabetes
February 19, 2021
“If it works in people as well as it does in animals, it’s possible that people will not be diabetic.”
DAPT increases bleeding without decreasing mortality in patients with coronary disease and diabetes
February 2, 2021
In patients who have diabetes with known coronary disease but without prior MI or stroke, what is the effect of dual-antiplatelet therapy (DAPT) with aspirin and ticagrelor on cardiovascular outcomes and bleeding events?
Protecting patients with diabetes from impact of COVID-19
January 28, 2021
Comprehensive report summarizes best practices to protect those with diabetes from impact of pandemic, from prior 2-day Diabetes Technology Society meeting.
Further warning on SGLT2 inhibitor use and DKA risk in COVID-19
January 19, 2021
Five new cases of euglycemic diabetic ketoacidosis seen in T2D patients with acute COVID-19 illness.
Biomarker HF risk score envisioned as SGLT2 inhibitor lodestar in diabetes
January 19, 2021
Together, four “easily measured” biomarkers predicted 5-year heart failure risk in patients with diabetes or prediabetes, potentially identifying best candidates for SGLT2 inhibitor therapy, some say.
Natural history of adrenal incidentalomas with and without mild autonomous cortisol excess
December 10, 2020
Is there significant change in the tumor size or hormonal function of benign nonfunctioning adrenal tumors (NFATs) or adenomas causing mild autonomous cortisol excess (MACE) over time?
Prioritize COVID-19 vaccination in both types of diabetes, say docs
December 9, 2020
The study is the first to prospectively evaluate COVID-19 severity factors and death in people with type 1 and type 2 diabetes separately.
Diabetic retinopathy may predict greater risk of COVID-19 severity
December 3, 2020
“Our study reports the first description of diabetic retinopathy as a potential risk factor for poor COVID-19 outcomes,” said the authors of a new study.
Blood glucose on admission predicts COVID-19 severity in all
November 30, 2020
Those with abnormally high glucose levels were more than twice as likely to die from the virus than were those with normal readings.